Lecture
This lecture covers preclinical and clinical trials in spinal muscular atrophy (SMA) gene therapy, discussing the demonstration of potency in mice, efficiency in patients, phase 1 trial results, further trials by Novartis, adverse effects, cellular targeting, and future perspectives in genome engineering and therapeutic strategies.